INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Praxis Precision Medicines, Inc. and its officers or directors [1] Financial Results - On August 4, 2025, Praxis reported its financial results for Q2 2025, including mid-stage study results for its anti-seizure medication vormatrigine [2] - In the study, 36 out of 61 patients experienced treatment-emergent adverse events, and nearly 25% of participants discontinued the study [2] Stock Market Reaction - Following the announcement of the study results, Praxis's stock price decreased by $3.00 per share, or 5.55%, closing at $51.09 per share on August 4, 2025 [3]